The antimicrobial dalbavancin represents one of the latest treatment options for skin infections and is now available on FDA-cleared microbroth dilution susceptibility plates, giving microbiology laboratories the means for susceptibility testing for fastidious Gram-positive organisms that cause acute bacterial skin and skin structure infections (ABSSSIs) in adults.
The Thermo Scientific Sensititre ID/AST System is the first to offer dalbavancin on IVD-labeled, microbroth dilution susceptibility plates. With one of the largest, most up-to-date selections of FDA-cleared antimicrobials, the Sensititre System enables laboratories to utilise dalbavancin, and over 240 other antimicrobials, to create custom plates tailored to their formulary, dilutions and patient population, eliminating offline tests and reducing costs. Dalbavancin is currently available on Sensititre custom plates, with plans to feature it on new standard plates in the future.
“The addition of dalbavancin to our antimicrobial offering is an important one for clinicians struggling to treat patients suffering from serious skin infections, particularly those that have shown resistance to other drugs,” said Mario Gualano, president, Thermo Fisher Scientific Microbiology. “By making this new compound widely available on the Sensititre platform, clinicians have another option in making decisions for the effective treatment of patients.”
The Sensititre System utilises true minimum inhibitory concentration (MIC) results, which are essential to fighting antimicrobial resistance by providing greater sensitivity for better resistance tracking. True MIC results are also the best measure of antibacterial effect, which can assist with therapeutic choices and promote overall better patient care.
Dalvance for injection (dalbavancin, Durata Therapeutics, an affiliate of Allergan) is approved by the FDA for the treatment of adults with skin infections caused by fastidious Gram-positive organisms, including: Streptococcus pyogenes, Streptococcus agalactiae, and Streptococcus anginosus group (including S. anginosus, S. intermedius, S. constellatus). It is the first drug with the Qualified Infectious Disease Product (QIDP) designation to receive FDA approval.
